A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Titel:
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Auteur:
Martín, M. Chan, A. Dirix, L. O’Shaughnessy, J. Hegg, R. Manikhas, A. Shtivelband, M. Krivorotko, P. Batista López, N. Campone, M. Ruiz Borrego, M. Khan, Q.J. Beck, J.T. Ramos Vázquez, M. Urban, P. Goteti, S. Di Tomaso, E. Massacesi, C. Delaloge, S.